CN107001372B - 取代的氨基嘌呤化合物、其组合物及其治疗方法 - Google Patents

取代的氨基嘌呤化合物、其组合物及其治疗方法 Download PDF

Info

Publication number
CN107001372B
CN107001372B CN201580065272.2A CN201580065272A CN107001372B CN 107001372 B CN107001372 B CN 107001372B CN 201580065272 A CN201580065272 A CN 201580065272A CN 107001372 B CN107001372 B CN 107001372B
Authority
CN
China
Prior art keywords
purin
cyclohexanecarboxamide
ylamino
chloro
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580065272.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107001372A (zh
Inventor
马修·亚历山大
索哥利·巴曼亚
约翰·弗雷德里克·博伊兰
约书亚·汉森
黄德华
罗伯特·哈伯德
布兰登·杰菲
吉姆·莱斯滕
迈赫兰·穆贾达姆
拉杰·K·拉赫加
希瑟·雷蒙
金佰利·施华兹
玛丽安·斯洛斯
艾杜亚度·托里斯
塔姆·明·特朗
徐水蟾
赵晶晶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Priority to CN202110381676.XA priority Critical patent/CN113248506A/zh
Publication of CN107001372A publication Critical patent/CN107001372A/zh
Application granted granted Critical
Publication of CN107001372B publication Critical patent/CN107001372B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580065272.2A 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法 Active CN107001372B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110381676.XA CN113248506A (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
US62/060,339 2014-10-06
PCT/US2015/053941 WO2016057370A1 (en) 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110381676.XA Division CN113248506A (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Publications (2)

Publication Number Publication Date
CN107001372A CN107001372A (zh) 2017-08-01
CN107001372B true CN107001372B (zh) 2021-04-27

Family

ID=55632334

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580065272.2A Active CN107001372B (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法
CN202110381676.XA Pending CN113248506A (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110381676.XA Pending CN113248506A (zh) 2014-10-06 2015-10-05 取代的氨基嘌呤化合物、其组合物及其治疗方法

Country Status (28)

Country Link
US (8) US9512124B2 (https=)
EP (2) EP3822274B1 (https=)
JP (4) JP6884701B2 (https=)
KR (2) KR102504849B1 (https=)
CN (2) CN107001372B (https=)
AR (2) AR102171A1 (https=)
AU (2) AU2015328414B2 (https=)
CA (1) CA2963639C (https=)
CL (1) CL2017000820A1 (https=)
CO (1) CO2017003838A2 (https=)
CY (1) CY1124173T1 (https=)
DK (1) DK3204386T3 (https=)
EA (1) EA201790779A1 (https=)
EC (1) ECSP17026210A (https=)
ES (2) ES2980464T3 (https=)
HR (1) HRP20210656T1 (https=)
HU (1) HUE054694T2 (https=)
IL (2) IL251566B (https=)
LT (1) LT3204386T (https=)
MX (2) MX388321B (https=)
PL (1) PL3204386T3 (https=)
PT (1) PT3204386T (https=)
RS (1) RS61884B1 (https=)
SG (2) SG11201702759XA (https=)
SI (1) SI3204386T1 (https=)
SM (1) SMT202100302T1 (https=)
TW (1) TW201629063A (https=)
WO (1) WO2016057370A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
CA3208587A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
BR112018001980A2 (pt) 2015-08-03 2018-09-18 Bristol Myers Squibb Co compostos cíclicos úteis como moduladores de tnf alfa
RS62496B1 (sr) * 2016-04-01 2021-11-30 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu
AU2017241837B2 (en) * 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CN109563095B (zh) * 2016-06-02 2021-10-29 细胞基因公司 动物和人抗疟剂
EP3464312A4 (en) * 2016-06-02 2019-11-27 Celgene Corporation ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
MX2020003620A (es) * 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
CN111417634A (zh) * 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法
CN117964497B (zh) * 2024-01-26 2026-03-31 江西凯信生物医药有限公司 一种3,3-二氟环戊胺盐酸盐的合成方法
CN121758295A (zh) * 2024-09-30 2026-03-31 青岛清原化合物有限公司 一种亚氨基芳基类化合物及中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103087066A (zh) * 2005-01-13 2013-05-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) * 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US20090215744A1 (en) 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
NZ598071A (en) 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
WO2009130342A1 (es) 2008-04-23 2009-10-29 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
US20130034495A1 (en) 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
RS62496B1 (sr) 2016-04-01 2021-11-30 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103087066A (zh) * 2005-01-13 2013-05-08 西格诺药品有限公司 卤代芳基取代的氨基嘌呤、其组合物及其治疗方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor;Plantevin Krenitsky et al.;《Bioorganic & Medicinal Chemistry Letters》;20121231;第22卷(第3期);第1433-1438页 *

Also Published As

Publication number Publication date
AR102171A1 (es) 2017-02-08
PT3204386T (pt) 2021-05-31
CA2963639C (en) 2023-07-04
US9737541B2 (en) 2017-08-22
PL3204386T3 (pl) 2021-09-20
HUE054694T2 (hu) 2021-09-28
HRP20210656T1 (hr) 2021-07-23
MX388321B (es) 2025-03-19
TW201629063A (zh) 2016-08-16
JP7196270B2 (ja) 2022-12-26
EP3204386A1 (en) 2017-08-16
US20210128565A1 (en) 2021-05-06
JP2023027269A (ja) 2023-03-01
US10646493B2 (en) 2020-05-12
EP3822274B1 (en) 2024-03-06
US10149849B2 (en) 2018-12-11
EP3204386B1 (en) 2021-03-03
US20190091230A1 (en) 2019-03-28
CN113248506A (zh) 2021-08-13
AU2015328414B2 (en) 2020-03-19
KR102504849B1 (ko) 2023-03-02
DK3204386T3 (da) 2021-05-25
RS61884B1 (sr) 2021-06-30
US20200237768A1 (en) 2020-07-30
US20190336507A1 (en) 2019-11-07
US10398700B2 (en) 2019-09-03
MX2017004600A (es) 2017-06-30
AU2015328414A1 (en) 2017-04-27
AU2020201486B2 (en) 2021-07-08
JP2017530199A (ja) 2017-10-12
IL251566A0 (en) 2017-05-29
CL2017000820A1 (es) 2017-12-15
CA2963639A1 (en) 2016-04-14
IL277069B (en) 2022-05-01
SI3204386T1 (sl) 2021-08-31
ES2871142T3 (es) 2021-10-28
WO2016057370A1 (en) 2016-04-14
BR112017006998A2 (pt) 2018-01-16
SMT202100302T1 (it) 2021-07-12
EA201790779A1 (ru) 2017-09-29
JP2020033352A (ja) 2020-03-05
CY1124173T1 (el) 2022-05-27
SG10202009598VA (en) 2020-10-29
LT3204386T (lt) 2021-07-12
NZ730753A (en) 2024-02-23
IL277069A (en) 2020-10-29
IL251566B (en) 2020-09-30
JP6884701B2 (ja) 2021-06-09
EP3822274A1 (en) 2021-05-19
NZ767954A (en) 2024-02-23
ECSP17026210A (es) 2017-05-31
CN107001372A (zh) 2017-08-01
US10940152B2 (en) 2021-03-09
US20170296546A1 (en) 2017-10-19
ES2980464T3 (es) 2024-10-01
AU2020201486A1 (en) 2020-03-19
JP6987823B2 (ja) 2022-01-05
US20230158035A1 (en) 2023-05-25
JP2022033858A (ja) 2022-03-02
US20170042902A1 (en) 2017-02-16
KR20170063740A (ko) 2017-06-08
EP3204386A4 (en) 2018-04-18
US20160096841A1 (en) 2016-04-07
MX2021014531A (es) 2022-01-06
US11590139B2 (en) 2023-02-28
AR128748A2 (es) 2024-06-12
SG11201702759XA (en) 2017-05-30
US9512124B2 (en) 2016-12-06
CO2017003838A2 (es) 2017-07-11
KR20230035424A (ko) 2023-03-13

Similar Documents

Publication Publication Date Title
CN107001372B (zh) 取代的氨基嘌呤化合物、其组合物及其治疗方法
US20230116093A1 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EA031671B1 (ru) Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения
HK1241852B (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
BR112017006998B1 (pt) Composto de aminopurina substituído, composição farmacêutica compreendendo o mesmo, uso e método para preparar o referido composto e métodos in vitro e ex vivo de inibição de quinase
AU2015201030B2 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant